Lang F F, Miller D C, Koslow M, Newcomb E W
Department of Neurosurgery, New York University Medical Center, New York.
J Neurosurg. 1994 Sep;81(3):427-36. doi: 10.3171/jns.1994.81.3.0427.
To characterize some of the genetic events underlying the development of glioblastoma multiforme, the authors analyzed 65 astrocytic tumors (seven pilocytic astrocytomas, eight astrocytomas, 16 anaplastic astrocytomas, and 34 glioblastomas multiforme) for loss of heterozygosity for chromosome 17p, loss of heterozygosity for chromosomes 10p and 10q, amplification of the epidermal growth factor receptor (EGFR) gene, and amplification of the oncogenes N-myc, c-myc, and N-ras using Southern blot analysis. Alterations of the p53 gene (positive immunostaining for p53 protein in tumors with or without p53 gene mutations) in these 65 tumors were analyzed previously. None of the 65 tumors showed amplification or rearrangement of N-myc, c-myc, or N-ras oncogenes. The molecular analysis presented here demonstrates distinct variants of astrocytic tumors, with at least three genetic pathways leading to glioblastoma multiforme. One pathway was characterized by 43 astrocytomas with alterations in p53. Glioblastomas with p53 alterations may represent tumors that progress from lower-grade astrocytomas. This variant was more likely to show loss of chromosome 17p than tumors without p53 alterations (p < 0.04). Seventy-five percent of tumors with loss of one 17p allele demonstrated mutations in the p53 gene. Loss of chromosome 10 was associated with progression from anaplastic astrocytoma (13%) to glioblastoma (38%) (p < 0.04). Amplification of the EGFR gene was a rare (7%) but late event in tumor progression (p < 0.03). A second pathway was characterized by six astrocytomas without p53 alterations and may represent clinically de novo high-grade tumors. These tumors were more likely to show amplification of the EGFR gene (83%) than tumors with p53 alterations. Sixty percent of tumors with EGFR amplification also showed loss of chromosome 10; loss of chromosome 17p was infrequent in this variant. One or more alternative pathways were characterized by 16 astrocytomas without p53 alterations and with none of the genetic changes analyzed in this study. Glioblastomas are a heterogeneous group of tumors that may arise via multiple genetic pathways.
为了描述多形性胶质母细胞瘤发生发展过程中的一些基因事件,作者分析了65例星形细胞瘤(7例毛细胞型星形细胞瘤、8例星形细胞瘤、16例间变性星形细胞瘤和34例多形性胶质母细胞瘤),采用Southern印迹分析法检测17号染色体短臂杂合性缺失、10号染色体短臂和长臂杂合性缺失、表皮生长因子受体(EGFR)基因扩增以及癌基因N-myc、c-myc和N-ras的扩增情况。之前已分析了这65例肿瘤中p53基因的改变(p53基因突变或未突变的肿瘤中p53蛋白免疫染色阳性)。65例肿瘤均未显示N-myc、c-myc或N-ras癌基因的扩增或重排。本文所呈现的分子分析显示了星形细胞瘤的不同亚型,至少有三种基因途径可导致多形性胶质母细胞瘤。一种途径的特征是43例p53基因改变的星形细胞瘤。p53基因改变的胶质母细胞瘤可能代表从低级别星形细胞瘤进展而来的肿瘤。与无p53基因改变的肿瘤相比,该亚型更易出现17号染色体短臂缺失(p<0.04)。75%的一个17号染色体短臂等位基因缺失的肿瘤显示p53基因突变。10号染色体缺失与间变性星形细胞瘤(13%)进展为胶质母细胞瘤(38%)相关(p<0.04)。EGFR基因扩增在肿瘤进展中是一个罕见(7%)但较晚出现的事件(p<0.03)。第二种途径的特征是6例无p53基因改变的星形细胞瘤,可能代表临床上的原发性高级别肿瘤。与有p53基因改变的肿瘤相比,这些肿瘤更易出现EGFR基因扩增(83%)。60%的EGFR基因扩增的肿瘤也显示10号染色体缺失;该亚型中17号染色体短臂缺失较少见。一种或多种其他途径的特征是16例无p53基因改变且无本研究中所分析的基因变化的星形细胞瘤。胶质母细胞瘤是一组异质性肿瘤,可能通过多种基因途径发生。